Myriad Genetics Earns $2 Million Milestone From Schering-Plough | GenomeWeb

SALT LAKE CITY, Utah--Genomics company Myriad Genetics here recently announced that it has received a $2 million milestone payment from Schering-Plough as a result of new discoveries related to a gene involved in brain cancer. Further milestone and royalty payments may result from the research on the role of the MMAC1 gene in the pathogenesis of cancer in the future, Myriad added. The gene was discovered earlier in the year by Myriad and the University of Texas MD Anderson Cancer Center.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.